Menu

Home / Guides / GLP-1 for men

Sleep, hormones, muscle.

GLP-1 for Men (2026): Sleep Apnea, Testosterone, Muscle and What Trials Show

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated

GLP-1s work for men too: the labels report weight loss in men and women alike, and lifting helps keep muscle. In December 2024, Zepbound became the first FDA-approved medicine for moderate to severe obstructive sleep apnea in adults with obesity; sleep doctors say keep CPAP. Men were 67% to 72% of the volunteers in SURMOUNT-OSA (2024); testosterone gains on GLP-1s come from small studies, mostly alongside weight loss.

  • Sleep apnea: Zepbound is FDA-approved for it; keep your CPAP
  • Testosterone: small studies; rises mostly track weight loss
  • Muscle: pair protein with strength training from week one
Published by NexLifeLegitScript-certified

GLP-1 for men in brief: sleep apnea, testosterone, muscle and heart

Sleep apnea
Zepbound is approved for moderate to severe OSA with obesity; sleep doctors say keep CPAP too
Testosterone
Not an approved use; small studies show rises, mostly with weight loss
Muscle
Men may lose more of it than women without strength training, a 2025 advisory estimates
Heart
Wegovy, Ozempic and Mounjaro carry heart-risk uses; Zepbound doesn’t
Compounded medicines
Not studied in these trials

Questions about sleep apnea or testosterone? Call or text (949) 818-8000, any time.

Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.

The short version

Do GLP-1s work for men? Quick answers on sleep apnea and testosterone

GLP-1 medicines for men at a glance: the weight trials, sleep apnea, testosterone, muscle, fertility and compounded versions, from the labels, trials and a 2025 advisory
QuestionAnswer
Do they work for men?Zepbound’s label says weight fell regardless of sex. But men were only 32% of SURMOUNT-1 (2022), so its averages mostly reflect women.
Sleep apnea?Zepbound is approved for moderate to severe obstructive sleep apnea with obesity. In SURMOUNT-OSA (2024), breathing events fell 25.3 and 29.3 an hour at 52 weeks, vs 5.3 and 5.5 on placebo.
Testosterone?No GLP-1 is approved to treat low testosterone. Small, short studies show rises, mostly alongside weight loss.
Muscle?Without strength training, muscle may be 20% to 25% of the weight men lose, a 2025 joint advisory in Obesity estimates
Fertility?No effect on male fertility in the labels’ rat studies (Zepbound, Wegovy)
Compounded versions?Not FDA-approved, and not studied in these trials
  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • Zepbound is approved for moderate to severe obstructive sleep apnea with obesity; men were 67% and 72% of its two trials.
  • Breathing events fell 25.3 and 29.3 an hour on Zepbound, versus 5.3 and 5.5 on placebo; sleep doctors say keep CPAP.
  • Men were only 32% of SURMOUNT-1 (2022), so its averages mostly reflect women, though weight fell regardless of sex.
  • Testosterone: no GLP-1 is approved to treat low testosterone; small studies show rises, mostly as weight comes off.
  • Lift to keep muscle. Without strength training, muscle may be 20% to 25% of men’s weight loss, a 2025 joint advisory in Obesity estimates.
  • At NexLife, compounded tirzepatide is $115 a month on the 12-month plan; it isn’t FDA-approved for sleep apnea or any use.

At a glance

How do tirzepatide and semaglutide compare for men?

What each label says on the questions men ask most, side by side; the head-to-head trial is in tirzepatide vs. semaglutide. Your provider decides which, if either, suits you.

From the Zepbound and Mounjaro (August 2026), Wegovy (June 2026), Ozempic (May 2026) and Ozempic tablets (January 2026) prescribing information, and prices from LillyDirect, NovoCare and Medicare.gov, checked November 15, 2026. These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.
Tirzepatide: Zepbound, MounjaroSemaglutide: Wegovy, Ozempic
MakerEli LillyNovo Nordisk
Approved usesas of November 2026Zepbound: weight; moderate to severe sleep apnea with obesity. Mounjaro: type 2 diabetes, and its heart risk (added August 2026)Wegovy: weight; heart risk with heart disease; MASH, a fatty liver disease. Ozempic: type 2 diabetes, with a heart use and, for the pen, a kidney use
Form and doselabel rangeWeekly shot; 2.5 mg to start, 5 to 15 mg after (10 or 15 mg for sleep apnea)Wegovy: weekly pen up to 2.4 mg (7.2 mg HD) or a daily pill up to 25 mg. Ozempic: a weekly pen up to 2 mg, or a daily tablet up to 9 mg
Men in the main trials32% of SURMOUNT-1 (2022); 67% and 72% of SURMOUNT-OSA (2024)29% of Wegovy’s three weight trials; 72% of its heart trial, SELECT (2023)
Sleep apneaZepbound approved in December 2024: AHI fell 25.3 and 29.3 events an hour, vs 5.3 and 5.5 on placebo (SURMOUNT-OSA, 2024)Not an approved use
Hair loss in menlabel0.5% on Zepbound (7.1% of women)0.9% on Wegovy 2.4 mg (4% of women)
Male fertility in rat studieslabel section 13.1No effect on sperm, mating or fertilityNo effect on male fertility
Nausea, drug vs placebolabelZepbound 25% to 29% vs 8%Wegovy 2.4 mg 44% vs 16%
Self-pay, a monthchecked November 1, 2026Zepbound $299 to $449 at LillyDirect, by dose; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699. Mounjaro $499Wegovy pen $349; pill $149 to $299 (NovoCare)
Medicare2026 to 2027The $50 Bridge leaves out moderate to severe sleep apnea; a Part D plan may cover itThe $50 Bridge covers the Wegovy pen and pill if you qualify; list price $675 from January 1, 2027

NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works

Swipe the table sideways to see every column.

From the Zepbound and Mounjaro (August 2026), Wegovy (June 2026), Ozempic (May 2026) and Ozempic tablets (January 2026) prescribing information, and prices from LillyDirect, NovoCare and Medicare.gov, checked November 15, 2026. These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.

Your situation

Which GLP-1 suits your situation?

Pick the line that sounds like you. Each gives the label facts for that case; the prescribing decision is your provider’s.

  • If you snore or stop breathing at night

    Only Zepbound is approved for moderate to severe obstructive sleep apnea with obesity. The label measures it with a sleep study’s AHI of 15 or more. Keep using CPAP unless your doctor says otherwise.

  • If you have heart disease

    Wegovy is approved to lower the risk of heart attack, stroke and heart-related death in adults with established heart disease and overweight or obesity. Zepbound has no heart-risk approval.

  • If you have type 2 diabetes

    Mounjaro and Ozempic are the diabetes versions, and both now carry heart-risk uses. On insulin or a sulfonylurea, the labels suggest your provider may lower those doses to avoid low blood sugar.

  • If your testosterone is low

    No GLP-1 is approved to treat it. If extra weight is part of the cause, losing it may help, but testosterone therapy decisions stay with your doctor.

  • If you lift, or want to keep muscle

    Plan protein and resistance training from the first week. The 2025 advisory says protein alone likely won’t preserve muscle without structured strength work.

  • If you’re planning to have children

    Rat studies (Zepbound, Wegovy) found no effect on male fertility. In a small 2024 trial, sperm concentration held up on semaglutide but fell sharply on testosterone therapy. Tell your provider your plans.

Trials

Do GLP-1s work as well for men?

Weight fell regardless of sex: the labels report weight loss in men and women alike. But men were the minority in the main weight trials, only 32% of SURMOUNT-1 (2022), so the averages mostly describe women; in Zepbound’s sleep apnea trials, men were 67% and 72%.

Share of men, from the Zepbound label (revised August 2026, sections 14.1 and 14.2; SURMOUNT-1 and SURMOUNT-2 are its Studies 1 and 2) and the Wegovy label (revised June 2026, sections 6.1 and 14.1). These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.
TrialWho took partMen
SURMOUNT-1Zepbound, 20222,539 adults with obesity or overweight, no diabetes, 72 weeks32%
SURMOUNT-2Zepbound, 2023; type 2 diabetes938 adults, 72 weeks49%
SURMOUNT-OSAZepbound, 2024234 adults not using CPAP or other PAP and 235 using it, 52 weeks67% and 72%
Wegovy weight trialsthree, pooled2,116 adults on Wegovy 2.4 mg, up to 68 weeks29%
SELECTWegovy’s heart trial, 202317,604 adults aged 45 or older with heart disease and a BMI of 27 or more72%

Swipe the table sideways to see every column.

Share of men, from the Zepbound label (revised August 2026, sections 14.1 and 14.2; SURMOUNT-1 and SURMOUNT-2 are its Studies 1 and 2) and the Wegovy label (revised June 2026, sections 6.1 and 14.1). These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.

  • −14.0 to −18.5 cmwaist change on Zepbound in SURMOUNT-1 (2022), 72 weeksabout 5.5 to 7.3 inches; placebo −4.0 cm (Zepbound label)
  • −10.8 to −13.1 cmwaist change on Zepbound in SURMOUNT-2 (2023), with type 2 diabetes, 72 weeksplacebo −3.3 cm; 49% were men (Zepbound label)

Same results, mostly women’s data. Zepbound’s label says weight fell “irrespective of age, sex, race, ethnicity, baseline BMI, and glycemic status.” But neither label publishes an average for men. Men were under a third of SURMOUNT-1 (2022), so its 15.0% to 20.9% average loss (3.1% on placebo) mostly reflects women.

Belly fat. The labels report waist size, not visceral fat itself, and waists shrank well beyond placebo in both Zepbound trials above. The only visceral-fat scan in the studies here comes from a small semaglutide trial in men, described in the testosterone section.

Hair loss is rarer in men. It was reported by 0.5% of men on Zepbound, against 7.1% of women, and by 0.9% of men on Wegovy 2.4 mg, against 4% of women. More: tirzepatide hair loss.

Sleep apnea

Can Zepbound treat sleep apnea?

Yes. In December 2024, Zepbound became the first medicine approved for moderate to severe obstructive sleep apnea in adults with obesity. Breathing events fell 25.3 and 29.3 an hour on Zepbound, versus 5.3 and 5.5 on placebo; most volunteers were men. Sleep doctors say keep CPAP.

SURMOUNT-OSA (The New England Journal of Medicine, 2024), as reported in the Zepbound label (revised August 2026, section 14.2): adults with an AHI of 15 or more and a BMI of 30 or more, on the highest dose they tolerated, 10 or 15 mg a week. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
At 52 weeksStudy 5: not using CPAPStudy 6: using CPAP
Who took part234 adults, 67% men, average age 48235 adults, 72% men, average age 52
Breathing events an hour (AHI)change, Zepbound vs placebo−25.3 vs −5.3−29.3 vs −5.5
AHI, percent change−50.7% vs −3%−58.7% vs −2.5%
Remission, or mild sleep apnea without daytime sleepiness42.2% vs 15.9%50.2% vs 14.3%
Body weight−17.7% vs −1.6%−19.6% vs −2.3%

Swipe the table sideways to see every column.

SURMOUNT-OSA (The New England Journal of Medicine, 2024), as reported in the Zepbound label (revised August 2026, section 14.2): adults with an AHI of 15 or more and a BMI of 30 or more, on the highest dose they tolerated, 10 or 15 mg a week. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.

CPAP stays. The American Academy of Sleep Medicine says Zepbound belongs in sleep apnea care alongside PAP therapy, oral appliances or surgery, not as a replacement for PAP. Its patient sheet adds that people shouldn’t stop CPAP without medical advice, and that the drug isn’t for central sleep apnea.

The dose. For sleep apnea, the label’s maintenance dose is 10 or 15 mg a week, reached in 2.5 mg steps at least 4 weeks apart. Your provider decides yours.

Medicare. The $50 GLP-1 Bridge leaves out people with moderate to severe sleep apnea, but Medicare says a Part D plan may cover a GLP-1 for it. More: Medicare and GLP-1s.

Medicare.gov lists who isn’t eligible for the Bridge, including people who:

“Have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (but your Part D plan might cover your GLP-1s).”

Centers for Medicare & Medicaid Services, Weight loss drugs | Medicare

Testosterone

Do GLP-1s raise testosterone?

In small studies of men with obesity and low testosterone, levels rose, mostly as weight came off. No GLP-1 is FDA-approved to treat low testosterone.

A randomized trial (Diabetes, Obesity and Metabolism, 2024) and a review of 7 studies (Andrology, 2025), both peer-reviewed, read Nov. 12, 2026. Neither tested compounded semaglutide or tirzepatide.
StudyWho and how longWhat it found
Semaglutide vs testosterone therapyrandomized trial, Diabetes, Obesity and Metabolism, 202425 men with type 2 diabetes, obesity and low testosterone; randomized, open-label; 24 weeksTestosterone rose in both groups, more on testosterone therapy. Median weight fell from 115 to 99 kg on semaglutide, with less visceral fat on a DXA scan. Sperm concentration fell a median 67% on testosterone therapy and didn’t change significantly on semaglutide; erectile function improved only with testosterone therapy
Review of 7 studiesmeta-analysis, Andrology, 2025680 men in 7 studies of GLP-1 medicines; only one was randomizedTestosterone rose on GLP-1 medicines, and rose more with more weight loss. The authors say the studies can’t show a direct effect on the testes, and that well-designed trials are needed

Swipe the table sideways to see every column.

A randomized trial (Diabetes, Obesity and Metabolism, 2024) and a review of 7 studies (Andrology, 2025), both peer-reviewed, read Nov. 12, 2026. Neither tested compounded semaglutide or tirzepatide.

The limits. These studies are small and short, and in each the men also lost weight, so it’s unclear how much the medicine itself did. The president of the American Association of Clinical Endocrinology said in July 2025 that it’s unknown whether tirzepatide acts on testosterone directly, apart from weight loss, and that longer-term data are needed.

What the labels say. Nothing: neither the Zepbound nor the Wegovy label mentions testosterone. Their drug-interaction sections cover insulin, sulfonylureas and oral medicines only.

Already on testosterone therapy? The 2024 trial compared the two treatments rather than combining them, so the combination wasn’t tested there. Whether to use both is your provider’s call.

Fertility. In the labels’ rat studies, neither tirzepatide nor semaglutide affected male fertility. Testosterone therapy is a different story: in the 2024 trial, sperm concentration fell a median 67% on it.

“No effects of tirzepatide were observed on sperm morphology, mating, fertility, and conception.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026, section 13.1 (rat studies)

Muscle

How do men keep muscle on a GLP-1?

With protein and strength training from the start. A 2025 advisory estimates men lose more muscle than women when they skip structured strength work.

  • 20–25%of the weight men lose may be musclewithout structured strength training (modeling, 2025 advisory)
  • 80–120 gprotein a day, one target the advisory givesor 1.2 to 1.6 g per kg of body weight
  • 5.3 of 13.6 kglost in STEP 1 (Wegovy, 2021) was lean mass, on averagemuscle is about half of lean mass, the advisory notes

Low testosterone adds risk. The advisory lists lower testosterone and older age among the factors tied to muscle loss and to eating too little protein.

Lift, don’t just eat. Extra protein alone is likely inadequate to keep muscle without structured resistance training, the advisory says. It suggests an exercise physiologist or physical therapist where that helps. Daily protein ideas: what to eat on a GLP-1.

Mozaffarian and colleagues, a joint advisory of four medical and nutrition groups (Obesity, 2025). These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.

Heart

Do GLP-1s lower heart risk for men?

Some do, for certain adults: three of the four medicines on this page now carry a heart-risk use. Wegovy’s is for adults with heart disease; Ozempic’s and, since August 2026, Mounjaro’s are for adults with type 2 diabetes. Compounded semaglutide and tirzepatide aren’t FDA-approved for any use.

The details
WegovyAdults with established heart disease and obesity or overweight: lowers the risk of heart attack, stroke and heart-related death
OzempicAdults with type 2 diabetes and heart disease; also kidney outcomes in type 2 diabetes with chronic kidney disease
MounjaroAdults with type 2 diabetes at high risk of heart attack, stroke or heart-related death; added in August 2026
ZepboundNo heart-risk approval; its approved uses are weight and sleep apnea

What Wegovy’s heart trial found. In SELECT (N Engl J Med, 2023), as reported in Wegovy’s label, 17,604 adults aged 45 or older with heart disease and a BMI of 27 or more took Wegovy 2.4 mg or placebo; 72% were men. Over a median of 41.8 months, Wegovy cut the risk of a first heart attack, stroke or heart-related death by 20% compared with placebo (a hazard ratio of 0.80 in its label). This trial studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.

Safety

Who should skip a GLP-1, and which side effects need a call?

Stomach upset is the usual side effect. These are the cases the labels rule out, and the signs that need a call or emergency care.

The boxed warning. In rodent studies, tirzepatide and semaglutide caused thyroid C-cell tumors, and no one knows yet whether they do in people. Skip both if you or a close relative has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2. A past serious allergic reaction to either medicine rules it out too. Zepbound’s label also says it isn’t recommended for people with severe gastroparesis, a stomach that empties very slowly.

  • Severe or lasting belly pain, sometimes into the back: possible pancreatitis. Stop the medicine and call your provider right away.
  • Upper belly pain with fever, or yellowing skin or eyes: possible gallbladder disease. Call your provider.
  • Vomiting or diarrhea that won’t quit: dehydration can hurt the kidneys. Drink fluids and call.
  • Swollen face, lips or throat, or trouble breathing: a serious allergic reaction. Stop and get emergency care.
  • Sweating, shakiness or confusion on insulin or a sulfonylurea: low blood sugar. Treat it as you were shown, then tell your provider.
  • A neck lump, hoarseness or trouble swallowing: tell your provider.
  • A racing heartbeat at rest on Wegovy, whose label warns of a higher heart rate: tell your provider.

Before any surgery or procedure with anesthesia, tell the team you take a GLP-1. From the Zepbound (August 2026) and Wegovy (June 2026) prescribing information, boxed warnings and sections 4 and 5.

Alcohol

Neither the Zepbound nor the Wegovy label addresses drinking. The 2025 advisory says alcohol may worsen nausea and acid reflux on a GLP-1 and should be kept to a minimum. No GLP-1 is FDA-approved to treat alcohol use, so using one to drink less is off-label. If you drink, tell your provider how much.

Step by step

How do you start a GLP-1, step by step?

Six things to sort out with your provider first, from the labels and the guidance on this page. Your provider makes the call.

  1. Ask about sleep apnea. Snore or stop breathing at night? Only Zepbound is approved for moderate to severe obstructive sleep apnea with obesity, and the label measures it with a sleep study.
  2. Keep your CPAP. Don’t stop CPAP without medical advice, the American Academy of Sleep Medicine says.
  3. List your medicines. On insulin or a sulfonylurea, your provider may lower those doses to avoid low blood sugar. Mention testosterone therapy too.
  4. Plan protein and lifting. A 2025 advisory proposes 80 to 120 g of protein a day, with structured strength training. Have kidney disease? Ask first.
  5. Share your family plans. Planning to have children? Tell your provider.
  6. Know the warning signs. For severe or lasting belly pain, sometimes into the back, stop the medicine and call your provider right away.

The six steps above, in order. The labels and your provider’s advice come first.

Vial math

How many units is your tirzepatide dose?

It depends on your vial’s strength. Here are the label’s doses at one example strength, including the 10 or 15 mg it sets for sleep apnea.

Tirzepatide doses on Zepbound’s label, with the volume and units on a U-100 syringe at an example strength of 25 mg per mL, and what each dose is on the label; your vial’s label decides
DosemL at 25 mg/mLUnits (U-100)On the label
2.5 mg0.1 mL10 unitsStarting dose, for 4 weeks
5 mg0.2 mL20 unitsA weight-loss maintenance dose
7.5 mg0.3 mL30 unitsA step up
10 mg0.4 mL40 unitsMaintenance for weight or sleep apnea
12.5 mg0.5 mL50 unitsA step up
15 mg0.6 mL60 unitsThe maximum; maintenance for weight or sleep apnea

The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units. 25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Zepbound’s multi-dose vials come in a strength for each dose, 0.6 mL a dose, so read the strength on your own vial’s label. Your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide dosage calculator. On semaglutide? Use the semaglutide dosage chart.

“The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026, section 2.2, for sleep apnea

Cost

What does Zepbound cost for sleep apnea, with or without insurance?

With commercial coverage of Zepbound, Lilly’s card can bring the single-dose pen to as little as $25 a fill. Without coverage, LillyDirect charges $299 to $449 a month, by dose; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699 (checked November 15, 2026). Medicare depends on why you take it.

Prices from LillyDirect, Lilly’s terms, NovoCare (wegovy.com) and TrumpRx.gov; Medicare rules from Medicare.gov and CMS; checked November 1, 2026. Compounded prices are all in. Compounded medicines aren’t the brand-name products in the rows above.
Your situationWhat you’d payGood to know
Your plan covers Zepboundcommercial insuranceAs little as $25 a fill for the single-dose pen with Lilly’s savings card, up to $100 off a monthThe card ends December 31, 2026; Medicare and Medicaid can’t use it
No coverageZepbound at LillyDirect$299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 to 15 mg with a refill within 45 days$499 to $699 from 7.5 mg without the 45-day refill; a month is 28 days
Medicare, with moderate to severe sleep apneaDepends on your Part D planThe $50 Bridge leaves out sleep apnea, type 2 diabetes and fatty liver disease
Medicare, weight onlyGLP-1 Bridge, if you qualify$50 a month for the Zepbound KwikPen, Wegovy or FoundayoJuly 1, 2026 to December 31, 2027; prior authorization when Medicare asks
Type 2 diabetes, self-payMounjaro at LillyDirect$499 a month at every doseLilly’s self-pay terms apply
Wegovy insteadNovoCarePen $349, or $199 for each of a new patient’s first two fills through December 31, 2026; pill $149 to $299Wegovy’s list price falls to $675 on January 1, 2027
TrumpRx.govself-pay listingsThe makers’ prices: Zepbound starting at $299Orders for Zepbound vials go through LillyDirect
Compounded tirzepatide at NexLifeisn’t FDA-approved for sleep apnea or any use$115 a month on the 12-month plan, or $129 month to monthThe same at every dose, with no membership fee
Compounded semaglutide at NexLifeisn’t FDA-approved$95 a month on the 12-month plan, or $109 month to monthThe same at every dose

NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works

Swipe the table sideways to see every column.

Prices from LillyDirect, Lilly’s terms, NovoCare (wegovy.com) and TrumpRx.gov; Medicare rules from Medicare.gov and CMS; checked November 1, 2026. Compounded prices are all in. Compounded medicines aren’t the brand-name products in the rows above.

A year, side by side. Thirteen four-week LillyDirect fills at $449 come to $5,837; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699. On NexLife’s 12-month plan, compounded tirzepatide is $1,380 a year, or $1,548 month to month. Month to month, NexLife’s $129 is $156 under the $285 median of the 25 tirzepatide programs in our GLP-1 price index that publish a month-to-month price (checked Nov. 15, 2026). They’re different products: compounded tirzepatide isn’t FDA-approved, isn’t Zepbound and wasn’t tested in SURMOUNT-OSA (compounded vs. brand-name tirzepatide). Every Zepbound price by dose: Zepbound cost without insurance.

Have type 2 diabetes? NexLife’s providers prescribe compounded tirzepatide and semaglutide for weight loss. They aren’t a treatment for type 2 diabetes and don’t replace Mounjaro, Ozempic or your diabetes care.

Switching from another program? If you pay less for compounded tirzepatide or semaglutide with another licensed provider, NexLife’s Price Match Guarantee† matches that regular monthly price while your plan stays active.

At NexLife

What do you get with compounded tirzepatide or semaglutide at NexLife?

You get a licensed provider’s review, one price at any dose with no membership fee, a nutrition plan, a 1:1 coaching call and free expedited shipping. Compounded tirzepatide is $115 a month on the 12-month plan and semaglutide $95, or $129 and $109 month to month. Compounded medicines aren’t FDA-approved.

If a NexLife provider prescribes it, this is what comes with it.

  • Your provider decides

    A provider licensed in your state reviews your health history online and prescribes only if treatment fits you. If you’re not prescribed, there’s no charge for medication.

  • One price, any dose

    Compounded tirzepatide: $115 a month on the 12-month plan, $119 on 6 months, $125 on 3 months, or $129 month to month. Compounded semaglutide: $95 a month on the 12-month plan, $99 on 6 months, $105 on 3 months or $109 month to month. No membership fee.

  • Price Match Guarantee†

    Coming from another licensed provider? Show a receipt from the last 60 days and we match your regular monthly price for as long as your plan is active.

  • Two named pharmacies

    Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA), state-licensed 503A pharmacies, prepare your prescription. NexLife uses only pharmacies licensed in the states they ship to, and we handle them for you.

  • People who pick up

    Call or text (949) 818-8000, 24/7, for real people; physicians take medical questions during clinical hours. Every plan includes a nutrition plan and a 1:1 coaching call.

  • Paying and delivery

    Pay with Affirm, Klarna, Afterpay, or an HSA or FSA card; NexLife provides a letter of medical necessity. Free expedited shipping, usually sent within 1 to 2 business days.

Compounded tirzepatide isn’t FDA-approved, for sleep apnea or anything else, and isn’t Zepbound; a licensed provider prescribes it only when it offers a significant difference for you.

NexLife is LegitScript-certified and rated 4.8 out of 5 on Trustpilot from 407 reviews (read November 15, 2026).

Loved by our members

Real stories from NexLife members about their care and service.

A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.

★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗

  • ★★★★★Read on Trustpilot ↗

    “Fast delivery and easy to get a hold of when needing to talk with someone!”

    Browneyes

  • ★★★★★Read on Trustpilot ↗

    “So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”

    April

  • ★★★★★Read on Trustpilot ↗

    “Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”

    Ethan B.

  • ★★★★★Read on Trustpilot ↗

    “That’s a real site with good prices and plans!”

    Estefany L.

  • ★★★★★Read on Trustpilot ↗

    “Affordable, quick and easy. They could not have made it a smoother less stressful experience.”

    Andisheh K.

  • ★★★★★Read on Trustpilot ↗

    “Great communication. Easy to work with. They work to set you up for success.”

    Anthony C.

  • ★★★★★Read on Trustpilot ↗

    “Very happy so far”

    Tammy E.

  • ★★★★★Read on Trustpilot ↗

    “Fast service great communication!! Willing to work with you!”

    Bon

  • ★★★★★Read on Trustpilot ↗

    “Great service and excellent communication!”

    Gabrielle D.

  • ★★★★★Read on Trustpilot ↗

    “Easy and pricing not bad! Customer service was helpful in answering my questions.”

    Lyndy T.

  • ★★★★★Read on Trustpilot ↗

    “Good experience, great team”

    Mai S.

  • ★★★★★Read on Trustpilot ↗

    “Great communciation and was fast and reliable”

    Kiki

Names are shortened for privacy. Reviews are members’ opinions, not medical advice.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $115/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $95/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan, $1,140 paid upfront; $109/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

The NexLife Price Match Guarantee†

Paying less elsewhere?
Keep your price. Upgrade your care.

Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.

  1. 1Send a receipt from the last 60 days
  2. 2A NexLife provider reviews your prescription
  3. 3Pay your matched price, at every dose
Switch and keep my price

Locked while your plan is activeSame price at every doseNo membership fee

†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.

GLP-1s for men: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

Can men use Zepbound instead of a CPAP machine?

Not as a swap. The American Academy of Sleep Medicine says Zepbound belongs alongside PAP therapy, oral appliances or surgery, not in place of PAP, and its patient sheet says not to stop CPAP without medical advice. Zepbound is approved for moderate to severe sleep apnea in adults with obesity.

Is Zepbound FDA-approved for sleep apnea in men?

Yes, for adults of either sex: in December 2024, the FDA approved it for moderate to severe obstructive sleep apnea in adults with obesity. In its label’s trials, that meant an AHI of 15 or more breathing events an hour and a BMI of 30 or more. It isn’t for central sleep apnea.

Does Medicare’s GLP-1 Bridge cover men with sleep apnea?

No. Medicare’s $50 Bridge leaves out people with moderate to severe sleep apnea, type 2 diabetes or fatty liver disease; Medicare says a Part D plan might cover a GLP-1 for those instead. Without coverage, Zepbound is $299 to $449 a month at LillyDirect, by dose; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699.

Can men take a GLP-1 with testosterone therapy?

Your provider decides. Neither the Zepbound nor the Wegovy label mentions testosterone; their drug-interaction sections cover insulin, sulfonylureas and oral medicines. The one small 2024 trial here compared semaglutide with testosterone therapy instead of combining them, so the combination wasn’t tested in it.

How much protein do men need on a GLP-1?

Four medical and nutrition groups, in a 2025 advisory, propose 1.2 to 1.6 g per kg of body weight a day while losing weight, or a flat 80 to 120 g. They estimate muscle can be 20% to 25% of the weight men lose without structured strength training, so lift too. Kidney disease? Ask your provider first.

Do men lose as much weight on GLP-1s as women?

The labels don’t say. Zepbound’s says weight fell regardless of sex, but neither label gives an average for men, who were 32% of SURMOUNT-1 (2022). A 2025 advisory estimates men lose more muscle than women without strength training. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.

Do GLP-1s raise testosterone in men?

In small studies, yes, mostly as men lose weight. In a 2024 trial of 25 men with type 2 diabetes and low testosterone, testosterone rose on semaglutide and on testosterone therapy. No GLP-1 is approved for low testosterone, and the American Association of Clinical Endocrinology’s president said in July 2025 it’s unclear how much tirzepatide itself does.

Do GLP-1s affect sperm or fertility in men?

Not in the rat studies in the Zepbound and Wegovy labels, which found no effect on male fertility. In one small 2024 trial, sperm concentration fell a median 67% on testosterone therapy and didn’t change significantly on semaglutide. A 2025 review found only two studies that measured semen, too few to pool, so tell your provider if you’re planning children.

What should men know about GLP-1 trials?

Men made up 72% of Wegovy’s heart trial, SELECT (2023), and 67% to 72% of Zepbound’s sleep apnea trials, SURMOUNT-OSA (2024), the trials behind those approvals. Neither label gives separate weight-loss averages for men. These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide and semaglutide weren’t studied.

Do GLP-1s cause hair loss in men?

Less often than in women. In the label trials, 0.5% of men on Zepbound reported hair loss, against 7.1% of women, and 0.9% of men on Wegovy 2.4 mg, against 4% of women. These trials studied FDA-approved Zepbound and Wegovy; compounded versions weren’t studied.

Do GLP-1s reduce belly fat in men?

The labels measure waist size, not visceral fat itself, and waists shrank well beyond placebo. In SURMOUNT-1 (2022), waists shrank 14.0 to 18.5 cm (about 5.5 to 7.3 inches) on Zepbound over 72 weeks, versus 4.0 cm on placebo. Compounded tirzepatide wasn’t studied.

Can men drink alcohol on a GLP-1?

The labels don’t address it. A 2025 advisory says alcohol may worsen nausea and acid reflux on a GLP-1 and should be kept to a minimum. No GLP-1 is FDA-approved to treat alcohol use, so using one to drink less is off-label. If you drink, tell your provider how much.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

Checked every clinical fact against the labels and the sleep academy’s sheets, and every price at its seller, on October 25, 2026.

  • How we checked. Every clinical fact here comes from the prescribing information for Zepbound and Mounjaro (revised August 2026), Wegovy (June 2026), Ozempic (May 2026) and Rybelsus and Ozempic tablets (January 2026), the American Academy of Sleep Medicine’s fact sheets, or the study named beside it, all read on November 1, 2026. Prices come from LillyDirect, NovoCare, TrumpRx.gov, CMS and Medicare.gov, checked the same day. We don’t give dosing plans: your provider decides. Zepbound, Mounjaro and Foundayo are trademarks of Eli Lilly and Company; Ozempic, Wegovy and Rybelsus of Novo Nordisk. NexLife isn’t affiliated with either.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
  • How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves

Paying less elsewhere? We match it.†

You’ve got the facts. Next: a 3-minute check.

Tell us about your health online; a licensed provider decides if compounded tirzepatide or semaglutide fits you. Tirzepatide is $115 a month on the 12-month plan or $129 month to month, and semaglutide $95 a month on the 12-month plan or $109 month to month, the same at every dose.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. Zepbound (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 15, 2026.
  2. Zepbound (tirzepatide) prescribing information, revised August 2026, on DailyMed (National Library of Medicine). Read Nov. 15, 2026.
  3. Mounjaro (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 15, 2026.
  4. Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (revised June 2026). Read November 15, 2026.
  5. Wegovy (semaglutide) prescribing information, FDA copy (revised June 2026). Read Nov. 15, 2026.
  6. Ozempic (semaglutide) prescribing information, Novo Nordisk (revised May 2026). Read November 15, 2026.
  7. Ozempic (semaglutide) prescribing information, FDA copy (revised May 2026). Read Nov. 15, 2026.
  8. Rybelsus and Ozempic (semaglutide) tablets prescribing information, Novo Nordisk (revised January 2026). Read November 15, 2026.
  9. Rybelsus and Ozempic (semaglutide) tablets prescribing information, FDA copy (revised January 2026). Read Nov. 15, 2026.
  10. American Academy of Sleep Medicine: Zepbound provider fact sheet (SURMOUNT-OSA, N Engl J Med 2024;391:1193-1205). Read November 15, 2026.
  11. American Academy of Sleep Medicine: Zepbound patient fact sheet. Read November 1, 2026.
  12. SURMOUNT-2: Garvey WT, et al. The Lancet 2023;402:613-26. Citation checked October 25, 2026.
  13. Gregorič N, et al. Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes Metab, 2024 (doi:10.1111/dom.16042). Read Nov. 12, 2026.
  14. Salvio G, et al. Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: a systematic review and meta-analysis. Andrology, 2025;13(8):2022-2034. Read Nov. 12, 2026.
  15. American Association of Clinical Endocrinology: Tirzepatide shown to tackle hypogonadism (July 15, 2025). Read November 1, 2026.
  16. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity, 2025;33(8):1475-1503. Read Nov. 15, 2026.
  17. LillyDirect: Zepbound self-pay prices. Checked November 15, 2026.
  18. LillyDirect: Mounjaro self-pay prices. Checked November 15, 2026.
  19. Eli Lilly: Zepbound savings card and self-pay terms. Read November 15, 2026.
  20. Novo Nordisk: What to pay for Wegovy. Checked November 15, 2026.
  21. TrumpRx.gov: Zepbound. Checked November 15, 2026.
  22. CMS: Medicare GLP-1 Bridge. Read November 15, 2026.
  23. Medicare.gov: Weight loss drugs (who the Bridge covers and leaves out). Read November 15, 2026.
  24. Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 15, 2026.
  25. NexLife: GLP-1 price index. Compounded tirzepatide prices checked November 15, 2026.
  26. NexLife: pricing, every plan.